Contact — NMD Pharma
NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis – ION CHANNEL LIBRARY
NMD Pharma raises €35m to expand pipeline - European Pharmaceutical Manufacturer
NMD Pharma - YouTube
NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis :: Scrip
NMD Pharma - Crunchbase Company Profile & Funding
NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn
NMD Pharma
NMD PHARMA APS innovation strategy - GoodIP
NMD Pharma
NMD Pharma company information, funding & investors | Dealroom.co
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
NMD Pharma A/S | LinkedIn
Thomas Pedersen email address & phone number | NMD Pharma A/S CEO contact information - RocketReach
Management team — NMD Pharma
NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
Chasing Big Pharma rivals, NMD posts data on rare disease drug
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
NMD Pharma
NMD Pharma - PIR International
NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn
NMD Pharma
NMD Pharma
